Porphyria

Porphyria

Overview

Porphyrias are a group of rare metabolic disorders characterized by deficiencies in the heme biosynthesis pathway, leading to accumulation of porphyrins or their precursors. These disorders can present with either neurological manifestations (neuropathic porphyrias) or cutaneous photosensitivity (cutaneous porphyrias), or both. The neurological complications involve the peripheral nervous system, autonomic nervous system, and central nervous system, making this disease group highly relevant to neurodegeneration research[@puy2022].

Classification

Hepatic Porphyrias (Origin in Liver)

| Type | Enzyme Deficiency | Primary Manifestations |
|------|-------------------|------------------------|
| Acute intermittent porphyria (AIP) | Porphobilinogen deaminase (PBGD) | Neuropathic |
| Variegate porphyria (VP) | Protoporphyrinogen oxidase (PPOX) | Mixed |
| Hereditary coproporphyria (HCP) | Coproporphyrinogen oxidase (CPOX) | Mixed |
| Delta-aminolevulinic acid dehydratase deficiency (ALAD) | ALAD | Neuropathic |

Erythropoietic Porphyrias (Origin in Bone Marrow)

| Type | Enzyme Deficiency | Primary Manifestations |
|------|-------------------|------------------------|
| Congenital erythropoietic porphyria (CEP) | Uroporphyrinogen III synthase (UROS) | Cutaneous |
| Erythropoietic protoporphyria (EPP) | Ferrochelatase (FECH) | Cutaneous |
| X-linked protoporphyria (XLP) | Delta-aminolevulinic acid synthase (ALAS2) | Cutaneous |

Genetics

...

Porphyria

Overview

Porphyrias are a group of rare metabolic disorders characterized by deficiencies in the heme biosynthesis pathway, leading to accumulation of porphyrins or their precursors. These disorders can present with either neurological manifestations (neuropathic porphyrias) or cutaneous photosensitivity (cutaneous porphyrias), or both. The neurological complications involve the peripheral nervous system, autonomic nervous system, and central nervous system, making this disease group highly relevant to neurodegeneration research[@puy2022].

Classification

Hepatic Porphyrias (Origin in Liver)

| Type | Enzyme Deficiency | Primary Manifestations |
|------|-------------------|------------------------|
| Acute intermittent porphyria (AIP) | Porphobilinogen deaminase (PBGD) | Neuropathic |
| Variegate porphyria (VP) | Protoporphyrinogen oxidase (PPOX) | Mixed |
| Hereditary coproporphyria (HCP) | Coproporphyrinogen oxidase (CPOX) | Mixed |
| Delta-aminolevulinic acid dehydratase deficiency (ALAD) | ALAD | Neuropathic |

Erythropoietic Porphyrias (Origin in Bone Marrow)

| Type | Enzyme Deficiency | Primary Manifestations |
|------|-------------------|------------------------|
| Congenital erythropoietic porphyria (CEP) | Uroporphyrinogen III synthase (UROS) | Cutaneous |
| Erythropoietic protoporphyria (EPP) | Ferrochelatase (FECH) | Cutaneous |
| X-linked protoporphyria (XLP) | Delta-aminolevulinic acid synthase (ALAS2) | Cutaneous |

Genetics

Inheritance Patterns

• Autosomal dominant — AIP, VP, HCP (incomplete penetrance)
• Autosomal recessive — CEP, ALAD deficiency
• X-linked — XLP

Common Genetic Mutations

• AIP — Over 300 PBGD mutations identified
• VP — PPOX gene mutations
• CEP — UROS gene mutations
• EPP — FECH gene mutations (often compound heterozygous)

Pathophysiology

Heme Biosynthesis Pathway

The eight-step pathway involves:

Aminolevulinate synthase (ALAS) → 2. Aminolevulinate dehydratase (ALAD) → 3. Porphobilinogen deaminase (PBGD) → 4. Uroporphyrinogen III synthase (UROS) → 5. Uroporphyrinogen decarboxylase (UROD) → 6. Coproporphyrinogen oxidase (CPOX) → 7. Protoporphyrinogen oxidase (PPOX) → 8. Ferrochelatase (FECH)

Neuropathic Mechanisms

The neurological manifestations in porphyria result from:

ALA toxicity — Delta-aminolevulinic acid is:

• A precursor to porphyrins
• Structurally similar to GABA (gamma-aminobutyric acid)
• Neurotoxic at elevated levels
• An inhibitor of neuronal Na+/K+ ATPase

Heme deficiency — Impaired heme synthesis affects:

• Cytochrome P450 enzymes in [neurons](/entities/neurons)
• Mitochondrial function
• Myelin formation

Autonomic dysfunction — due to:

• Peripheral neuropathy affecting autonomic fibers
• Direct effects of porphyrin precursors

Oxidative stress — Porphyrins can generate [reactive oxygen species](/entities/reactive-oxygen-species)[@mustajoki1993]

Precipitating Factors

• Drugs — Barbiturates, sulfonamides, oral contraceptives, certain antiepileptics
• Hormonal factors — Menstruation, pregnancy
• Dietary factors — Fasting, low-carbohydrate diets
• Stress — Physical or psychological stress
• Infections — Various infections can trigger attacks

Clinical Features

Acute Neuropathic Porphyria (AIP, VP, HCP)

Abdominal Manifestations

• Severe abdominal pain (most common)
• Nausea and vomiting
• Constipation or diarrhea
• Abdominal distension
• Tachycardia
• Hypertension

Neurological Manifestations

• Peripheral neuropathy — Motor > sensory
• Weakness (proximal, often starting in upper extremities)
• Sensory loss
• Reflex changes
• May progress to respiratory failure
• Autonomic neuropathy
• Tachycardia
• Hypertension
• Sweating abnormalities
• Urinary retention
• Central nervous system
• Seizures
• Confusion
• Hallucinations
• Coma
• Psychiatric symptoms (anxiety, depression, psychosis)

Skin Manifestations (VP, HCP)

• Photosensitivity
• Bullae and vesicles
• Skin fragility
• Hypertrichosis
• Pigmentation changes

Chronic Manifestations

• Chronic pain
• Chronic kidney disease (due to recurrent attacks)
• Hypertension
• Peripheral neuropathy (may persist between attacks)
• Hepatocellular carcinoma risk (elevated in AIP)

Diagnosis

Laboratory Findings During Acute Attack

Elevated aminolevulinic acid — in urine (most sensitive for acute attacks)

Elevated porphobilinogen — in urine (diagnostic for acute porphyrias)

Normal porphyrins — in between attacks

Between Attacks

• Urine PBGD may remain elevated in AIP
• Enzyme activity testing (erythrocyte PBGD for AIP)
• Genetic testing for specific mutations

Special Testing

• Wood's lamp examination — urine may fluoresce
• Plasma porphyrin scan — for VP
• Fecal porphyrins — elevated in VP and HCP

Differential Diagnosis

• Acute abdomen (surgical conditions)
• Guillain-Barré syndrome
• Multiple sclerosis
• Psychiatric disorders
• Other metabolic neuropathies

Treatment

Acute Attack Management

Heme Therapy

• Hematin (heme arginate) — IV administration

-抑制s ALA synthase (rate-limiting enzyme)

• Reduces porphyrin precursor accumulation
• Most effective when given early in attack
• Dose: 3-4 mg/kg/day for 4 days

Symptomatic Management

• Pain management — Opioids (meperidine often used)
• Nausea/vomiting — Ondansetron, promethazine
• Autonomic dysfunction — Beta-blockers for tachycardia/hypertension
• Seizures — GABAergic agents (avoid precipitating drugs)
• Respiratory failure — Mechanical ventilation if needed

Chronic Management

Avoid precipitating factors — Drug avoidance, adequate nutrition

Carbohydrate loading — During prodrome or mild attacks

Prophylactic heme — For frequent attackers

Liver transplantation — For severe, refractory cases

Gene therapy — Experimental approaches

Cutaneous Porphyria Management

• Sun protection — Broad-spectrum sunscreen, protective clothing
• Avoidance of triggering drugs
• Beta-carotene — May reduce photosensitivity
• Hematin — May help in some cases
• Liver evaluation — Monitor for hepatic complications

Prognosis

• With appropriate management — Generally good, low mortality
• Untreated acute attacks — Can be fatal due to respiratory complications
• Recurrent attacks — Lead to chronic kidney disease and neuropathy
• Long-term — Risk of hepatocellular carcinoma requires surveillance

Neurological Research Implications

Porphyria provides a unique model for understanding:

• Heme metabolism in neuronal function
• ALA-mediated neurotoxicity
• Drug-induced neuropathy
• Autonomic dysfunction
• The role of oxidative stress in neurodegeneration

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Puy et al., Porphyria: a 2022 update (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35040452/)

[Unknown, Mustajoki & Nordmann, Acute intermittent porphyria (1993) (1993)](https://pubmed.ncbi.nlm.nih.gov/8127169/)

[Unknown, Kauppinen, Porphyria diagnosis and treatment (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15929753/)

[Stein et al., Heme arginate therapy in acute porphyria (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28976923/)

[Elder et al., Update on porphyria genetics (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24033263/)